Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 11, 2020

Antidepressant use limits serotonin as a marker for neuroendocrine tumor disease activity by lowering of circulating serotonin concentrations

  • Huub H. van Rossum EMAIL logo , Jocelyn Spruit , Catharina M. Korse , Froukje E. de Vries and Margot E.T. Tesselaar
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Verbeek WH, Korse CM, Tesselaar ME. Gep-nets update: secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol 2016;174:R1–7.10.1530/EJE-14-0971Search in Google Scholar PubMed

2. Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000;747: 33–48.10.1016/S0378-4347(00)00341-8Search in Google Scholar

3. Korse CM, Buning-Kager J, Linders TC, Heijboer AC, van den Broek D, Tesselaar ME, et al. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clin Chim Acta 2017;469:130–5.10.1016/j.cca.2017.04.001Search in Google Scholar PubMed

4. Peters MA, van Faassen M, de Jong WH, Bouma G, Meijer C, Walenkamp AM, et al. Use of selective serotonin reuptake inhibitors is associated with very low plasma free serotonin concentrations in humans. Ann Clin Biochem 2019; doi: 10.1177/0004563219880567. [Epub ahead of print].Search in Google Scholar PubMed

5. Abdelmalik N, Ruhe RG, Barwari K, van den Dool EJ, Meijers JC, Middeldorp S, et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Throm Haemost 2008;6:2168–74.10.1111/j.1538-7836.2008.03196.xSearch in Google Scholar PubMed

6. Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 2012;141:343–51.10.1016/j.jad.2012.03.025Search in Google Scholar PubMed

7. van Faassen M, Bouma G, de Hosson LD, Peters MA, Kats-Ugurlu G, de Vries EG, et al. Quantitative profiling of platelet-rich plasma indole markers by direct-matrix derivatization combined with LC-MS/MS in patients with neuroendocrine tumors. Clin Chem 2019;65:1388–96.10.1373/clinchem.2019.305359Search in Google Scholar PubMed

8. Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA. Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992;38:1730–6.10.1093/clinchem/38.9.1730Search in Google Scholar

Received: 2019-10-28
Accepted: 2019-11-27
Published Online: 2020-01-11
Published in Print: 2020-09-25

©2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 23.4.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2019-1111/html
Scroll to top button